• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study.

作者信息

Tse Gary, Lee Sharen, Liu Tong, Zhou Jiandong

机构信息

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, 300211, China.

School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China.

出版信息

Cardiovasc Drugs Ther. 2024 Apr;38(2):391-392. doi: 10.1007/s10557-024-07550-8. Epub 2024 Jan 20.

DOI:10.1007/s10557-024-07550-8
PMID:38244149
Abstract
摘要

相似文献

1
Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study.与二肽基肽酶4抑制剂相比，钠-葡萄糖协同转运蛋白2抑制剂预防不良心血管结局的需治疗人数：香港糖尿病研究
Cardiovasc Drugs Ther. 2024 Apr;38(2):391-392. doi: 10.1007/s10557-024-07550-8. Epub 2024 Jan 20.
2
Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.比较钠-葡萄糖共转运蛋白 2 抑制剂和二肽基肽酶-4 抑制剂对香港糖尿病患者新发心房颤动、卒中和死亡率风险的影响：一项倾向评分匹配研究。
Cardiovasc Drugs Ther. 2023 Jun;37(3):561-569. doi: 10.1007/s10557-022-07319-x. Epub 2022 Feb 10.
3
Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.在中国香港，钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂的使用与 2 型糖尿病患者发生阻塞性气道疾病和加重事件的风险相关。
JAMA Netw Open. 2023 Jan 3;6(1):e2251177. doi: 10.1001/jamanetworkopen.2022.51177.
4
Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.比较钠-葡萄糖共转运蛋白 2 抑制剂和二肽基肽酶-4 抑制剂对新发抑郁症的影响：香港一项倾向评分匹配研究。
Acta Diabetol. 2023 Jul;60(7):917-927. doi: 10.1007/s00592-023-02063-6. Epub 2023 Mar 31.
5
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂治疗的糖尿病患者新发晕厥：一项基于中国人群的队列研究。
Eur Heart J Cardiovasc Pharmacother. 2024 Feb 23;10(2):103-117. doi: 10.1093/ehjcvp/pvad086.
6
Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis.比较钠-葡萄糖共转运蛋白 2 抑制剂和二肽基肽酶-4 抑制剂治疗 2 型糖尿病患者的心血管结局和代谢危险因素：一项荟萃分析。
Eur J Prev Cardiol. 2022 Jan 11;28(16):1840-1849. doi: 10.1093/eurjpc/zwab099.
7
Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.与二肽基肽酶-4 抑制剂相比，钠-葡萄糖共转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂添加后心血管事件的初次发生：一项糖尿病退伍军人队列研究。
Ann Intern Med. 2023 Jun;176(6):751-760. doi: 10.7326/M22-2751. Epub 2023 May 9.
8
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.在日本真实世界行政数据库研究中，新接受钠-葡萄糖共转运蛋白 2 抑制剂治疗的 2 型糖尿病患者与接受二肽基肽酶-4 抑制剂治疗的患者的心血代谢风险降低情况。
J Diabetes Investig. 2023 Mar;14(3):404-416. doi: 10.1111/jdi.13952. Epub 2022 Dec 14.
9
Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶 4 抑制剂在 2 型糖尿病新发总体癌症中的比较：一项基于人群的研究。
Cancer Med. 2023 Jun;12(11):12299-12315. doi: 10.1002/cam4.5927. Epub 2023 May 6.
10
The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂治疗 2 型糖尿病患者新发心房颤动的风险：一项全国性队列研究。
Cardiovasc Diabetol. 2022 Jun 28;21(1):118. doi: 10.1186/s12933-022-01549-x.

引用本文的文献

1
Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis.二肽基肽酶-4抑制剂与心血管结局的全球研究趋势：一项全面的文献计量分析
Ann Med Surg (Lond). 2025 Mar 27;87(4):2133-2148. doi: 10.1097/MS9.0000000000003089. eCollection 2025 Apr.

本文引用的文献

1
Comment on "Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients".关于“钠-葡萄糖协同转运蛋白2抑制剂与二肽基肽酶-4抑制剂对糖尿病患者新发房颤、中风及死亡风险的比较”的评论
Cardiovasc Drugs Ther. 2024 Feb;38(1):201-202. doi: 10.1007/s10557-023-07527-z. Epub 2023 Nov 27.
2
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection.急性心力衰竭中SGLT2抑制剂的早期应用：聚焦利尿和肾脏保护
Cardiovasc Drugs Ther. 2025 Jun;39(3):687-690. doi: 10.1007/s10557-023-07512-6. Epub 2023 Oct 13.
3
Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.
新型抗糖尿病药物心血管结局的荟萃分析所需治疗人数。
ESC Heart Fail. 2023 Feb;10(1):552-567. doi: 10.1002/ehf2.14213. Epub 2022 Nov 7.
4
Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.比较钠-葡萄糖共转运蛋白 2 抑制剂和二肽基肽酶-4 抑制剂对香港糖尿病患者新发心房颤动、卒中和死亡率风险的影响：一项倾向评分匹配研究。
Cardiovasc Drugs Ther. 2023 Jun;37(3):561-569. doi: 10.1007/s10557-022-07319-x. Epub 2022 Feb 10.
5
Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂使用者中的心力衰竭和心肌梗死事件。
ESC Heart Fail. 2022 Apr;9(2):1388-1399. doi: 10.1002/ehf2.13830. Epub 2022 Feb 7.